544. Severe COVID-19 in Children and Young Adults in the Washington DC Metropolitan Region

DeBiasi, Roberta L.; Song, Xiaoyan; Ansusinha, Emily; Smith, Karen L.; Bell, Michael J.; Pershad, Jay; Hahn, Andrea; Hamdy, Rana F.; Hanisch, Benjamin; Harik, Nada; Jantausch, Barbara; Koay, Wei Li Adeline; Campos, Joseph M.; Delaney, Meghan; Simpson, Joelle; Cora‐Bramble, Denice; Wessel, David

doi:10.1093/ofid/ofaa439.738

Cited by 45 publications

(70 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48 Several studies have observed no difference in obesity rates between children with mild vs. severe COVID-19 disease. [50][51][52] While obesity in paediatric patients hospitalized for COVID-19 is not more frequent than in the general paediatric population, COVID-19 disease severity may be associated with obesity, as in adults. One report of 50 paediatric patients hospitalized with COVID-19 identified obesity as a risk factor for mechanical ventilation.…”

Section: Current Evidence Does Not Suggest That Central Hormone Deficiencies Increase Risk Of Acquiring Sars-cov-2 Infectionmentioning

confidence: 99%

SARS‐CoV‐2 infection and paediatric endocrine disorders: Risks and management considerations

Ashraf

Gourgari

et al. 2021

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Background Coronavirus‐19 (COVID‐19) is a disease caused by the SARS‐CoV‐2 virus, the seventh coronavirus identified as causing disease in humans. The SARS‐CoV‐2 virus has multiple potential pathophysiologic interconnections with endocrine systems, potentially causing disturbances in glucose metabolism, hypothalamic and pituitary function, adrenal function and mineral metabolism. A growing body of data is revealing both the effects of underlying endocrine disorders on COVID‐19 disease outcome and the effects of the SARS‐CoV‐2 virus on endocrine systems. However, comprehensive assessment of the relationship to endocrine disorders in children has been lacking. Content In this review, we present the effects of SARS‐CoV‐2 infection on endocrine systems and review the current literature on complications of COVID‐19 disease in underlying paediatric endocrine disorders. We provide recommendations on management of endocrinopathies related to SARS‐CoV‐2 infection in this population. Summary and outlook With the surge in COVID‐19 cases worldwide, it is important for paediatric endocrinologists to be aware of the interaction of SARS‐CoV‐2 with the endocrine system and management considerations for patients with underlying disorders who develop COVID‐19 disease. While children and adults share some risk factors that influence risk of complications in SARS‐CoV‐2 infection, it is becoming clear that responses in the paediatric population are distinct and outcomes from adult studies cannot be extrapolated. Evidence emerging from paediatric studies provides some guidance but highlights the need for more research in this area.

show abstract

Section: Current Evidence Does Not Suggest That Central Hormone Deficiencies Increase Risk Of Acquiring Sars-cov-2 Infectionmentioning

confidence: 99%

SARS‐CoV‐2 infection and paediatric endocrine disorders: Risks and management considerations

Ashraf

Gourgari

et al. 2021

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

show abstract

“…10 Also a multi-system inflammatory syndrome is reported among children by WHO. 12 The report describes that, clusters of children and adolescents requiring hospital admission with a multisystem inflammatory condition, and some features similar to Kawasaki disease and toxic shock syndrome, in continents like Europe and North America 13 , 14 , 15 …”

Section: Discussionmentioning

confidence: 99%

A cross-sectional study on COVID19 mortality among people below 30 years of age in Tamilnadu-2020

Anand¹,

Yogaraj²,

Priya³

et al. 2021

Clinical Epidemiology and Global Health

View full text Add to dashboard Cite

Introduction The COVID19 pandemic has turned out to be one of the public health* burdens in 2020. The fear of deaths due to COVID19 has surmounted even in developed countries and hasn't spared young age. This study aims in assessing the mortality due to COVID19 among patients below 30years of age in TamilNadu. Methods The data was collected from a publicly available secondary data source( www.stopcorona.tn.gov.in )which is an official COVID19 state dashboard. Details of the young COVID19 deaths* under 30yrs of age, their gender, symptoms, Co-morbidities, date of symptoms, date of admission, and death were collected till October 2020. A total of 158 deaths were included in the analysis. Fischer exact test and Mann Whitney U test* were used and p-value <0.05 was considered significant. Results Among the 158 COVID19 deaths under 30 years of age, the median age affected was 25 years(IQR-7) and 70.3% (n-111) had at least one co-morbidity*. The median time interval between symptom onset and hospital admission was 3 days (IQR-3) and between admission and death was 4 days(IQR-7).There was a significant association of myocarditis, refractory seizures, Central nervous system involvement as the cause of death in the age group 0–15years, compared with 16–30years(p < 0.05). The majority of deaths occurred with a late presentation, also patients with higher age were admitted after 2 days of symptoms and the results were statistically significant(p < 0.05). Conclusion Understanding the age-dependent risk gradient and their trend of this new virus at young age* is essential for public health planning and prevent future deaths, future research gateways.

show abstract

“…Despite being an unusual manifestation, the increase in the number of reported associations between Kawasaki Disease (KD) and COVID-19 in children raises new concerns about its consequences. 5,6 Search Methods: In order to develop a nonsystematic narrative review, we executed literature searches in multiple databases (Google Scholar, PubMed, SciELO, and Medscape) with no time restriction for articles published in English. Search terms included the keywords: "Sars-CoV-2", "COVID-19", "Kawasaki-like", "MIS-C", "PIMS-TS" and "Autoimmune disease".…”

mentioning

confidence: 99%

Kawasaki-Like Disease, a New Phenotype in Sars-CoV-2?

Chara¹,

Rickli²,

Silva³

et al. 2021

International Journal of Cardiovascular Sciences

View full text Add to dashboard Cite

The coronavirus disease , that assumed pandemic proportions in March 2020, mainly affects the respiratory tract, causing severe interstitial pneumonia in adults. Worldwide data indicate that COVID-19 tends to be more benign in children, which is evidenced by a high incidence of asymptomatic or mild upper airways' infection cases in this population. However, recent studies have been associating Kawasaki-like symptoms as a nonclassical presentation of coronavirus disease in pediatrics. It is suggested that the intense cytokine cascade, promoted by the SARS-CoV-2 infection, can trigger a multisystem inflammatory response as an atypical Kawasaki form in genetically predisposed individuals. In this context, patients may develop more severe clinical features with a greater predisposition to myocardial involvement, Macrophage Activation Syndrome, and Kawasaki Disease Shock Syndrome. Despite critical conditions, patients usually respond to conventional treatment of Kawasaki Disease with intravenous immunoglobulin. This article intends to provide an approach to the association between Kawasaki-Like Syndrome and COVID-19. BackgroundThe Sars-CoV-2 virus was initially isolated in the city of Wuhan, China, during a pneumonia outbreak of unknown cause in December 2019, a disease then named COVID-19. Due to its progressive worldwide spread, the World Health Organization decreed, three months later, the state of pandemic. 1 Sars-CoV-2 usually affects the respiratory tract, causing severe interstitial pneumonia in adults. In children, however, it tends to be more benign, manifesting asymptomatically or as a mild infection of upper airways. A systematic review that assessed a 12-case series of children from China found that 39%-82% of the patients with COVID-19 developed a moderate course of the disease. 2 A minority of pediatric cases presented severity, with respiratory failure, shock, coagulation dysfunction, and renal injury. 3,4 Data from many countries indicate that the rate of Sars-CoV-2 infection in the population under 18 is low, ranging from 1%-2%. Among the cases, the occurrence of unfavorable outcomes is even rarer. A cohort study by DeBiasi et al., 5 with 177 young patients diagnosed with coronavirus disease found that 44 (24.8%) patients needed hospitalization, among these, only 9 (2.8%) were critically ill. 5 Interestingly, one of them developed hypotension and myocardial depression associated with signs of hyperinflammatory state, a Kawasaki-like presentation. Despite being an unusual manifestation, the increase in the number of reported associations between Kawasaki Disease (KD) and COVID-19 in children raises new concerns about its consequences. 5,6 Search Methods: In order to develop a nonsystematic narrative review, we executed literature searches in multiple databases (Google Scholar, PubMed, SciELO, and Medscape) with no time restriction for articles published in English. Search terms included the keywords: "Sars-CoV-2", "COVID-19", "Kawasaki-like", "MIS-C", "PIMS-TS" and "Autoimmune disease". We emphasized i...

show abstract

544. Severe COVID-19 in Children and Young Adults in the Washington DC Metropolitan Region

Cited by 45 publications

References 0 publications

SARS‐CoV‐2 infection and paediatric endocrine disorders: Risks and management considerations

SARS‐CoV‐2 infection and paediatric endocrine disorders: Risks and management considerations

A cross-sectional study on COVID19 mortality among people below 30 years of age in Tamilnadu-2020

Kawasaki-Like Disease, a New Phenotype in Sars-CoV-2?

Contact Info

Product

Resources

About